Semaglutide (Ozempic, Wegovy, Rybelsus) was the drug that made GLP-1 weight loss mainstream. Retatrutide could double its efficacy. This page covers the science, the data, and the practical reality.
Head-to-head table
| Measure | Retatrutide 12 mg | Semaglutide 2.4 mg | Difference |
|---|---|---|---|
| Class | Triple agonist (GLP-1+GIP+glucagon) | Single agonist (GLP-1) | — |
| Weight loss avg | 24.2% (Phase 2, 48w) | 14.9% (Phase 3 STEP-1, 68w) | +9.3 pp (retatrutide) |
| ≥10% weight loss | 90%+ | ~70% | retatrutide higher |
| A1C reduction (T2D) | −2.0% | −1.8% | ~same |
| FDA approval | No (Phase 3) | Yes (2017 T2D, 2021 obesity) | — |
| US availability | Not available | All pharmacies + telehealth | — |
| Brand names | — | Ozempic, Wegovy, Rybelsus | — |
| Telehealth $/mo cash | — | $179–$299 | — |
| Nausea | 55% | 40% | retatrutide higher |
| Diarrhea | 32% | 30% | ~same |
Mechanism: why the gap is so big
Semaglutide hits one receptor. Retatrutide hits three. Each additional receptor has produced more weight loss when added to the mix. The evolution:
- GLP-1 alone (semaglutide): ~15% weight loss. Appetite suppression + slowed gastric emptying + improved insulin.
- GLP-1 + GIP (tirzepatide): ~22% weight loss. Adds insulin sensitivity and better fat handling.
- GLP-1 + GIP + glucagon (retatrutide): ~24% weight loss. Adds energy expenditure and hepatic fat oxidation.
That's why some people in patient communities refer to retatrutide as "GLP-3" — not a real pharmacology term, but a shorthand for the evolution.
Side effects comparison
Semaglutide's side-effect profile is well-characterized after a decade of use. Retatrutide's is still emerging. Early data suggests retatrutide has slightly higher GI burden (likely the glucagon effect).
Cost comparison
| Channel | Semaglutide $/mo | Retatrutide $/mo |
|---|---|---|
| Telehealth (compounded) | $179–$299 | Not available via licensed telehealth |
| Branded (Wegovy / Rybelsus) | $1,349 cash | n/a |
| Compounded (pharmacy) | Tightening post-shortage | $300–$500 |
| Research peptide | Available but discouraged | ~$260/mo unsupervised |
Who should pick which
- You want maximum weight loss, fast, supervised: tirzepatide (closer in efficacy to retatrutide, also FDA-approved).
- You want the most well-proven GLP-1 with extensive long-term data: semaglutide.
- You want retatrutide specifically: clinical trial or wait for FDA approval (2027–2028).
- Budget-constrained: semaglutide at $179/mo via telehealth is the lowest-cost supervised option.
The verdict
Retatrutide's 9-point weight-loss advantage over semaglutide is real and significant. For people with severe obesity (BMI >40) and a lot to lose, that gap matters. But semaglutide is available today and well-characterized; retatrutide is years away. Start with semaglutide or tirzepatide now. Evaluate retatrutide when it's actually on the market.